Literature DB >> 15616321

Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.

Jan Rupp1, Andreas Gebert, Werner Solbach, Matthias Maass.   

Abstract

Quinolone resistance of Chlamydia pneumoniae has not been described previously. Serial subcultures of C. pneumoniae under increasing moxifloxacin concentrations (0.0125 to 6.4 mg/liter) resulted in a 256-fold MIC increase compared to moxifloxacin-naive strains. GyrA gene sequencing revealed a novel point mutation with a Ser-->Asn substitution. Subcultures under rifalazil and macrolides did not alter the respective MICs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15616321      PMCID: PMC538918          DOI: 10.1128/AAC.49.1.406-407.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Int J Antimicrob Agents       Date:  2000-07       Impact factor: 5.283

3.  Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations.

Authors:  I Morrissey; H Salman; S Bakker; D Farrell; C M Bébéar; G Ridgway
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

Review 4.  Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.

Authors:  C H Nightingale
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

5.  Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals.

Authors:  M J Everett; Y F Jin; V Ricci; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Authors:  Sheila Malay; Patricia M Roblin; Tamara Reznik; Andrei Kutlin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

8.  In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.

Authors:  Naoyuki Miyashita; Hiroshi Fukano; Koichiro Yoshida; Yoshihito Niki; Toshiharu Matsushima
Journal:  J Infect Chemother       Date:  2002-03       Impact factor: 2.211

9.  Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.

Authors:  Satoshi Ameyama; Yuko Shinmura; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.

Authors:  J Gieffers; W Solbach; M Maass
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  6 in total

Review 1.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.

Authors:  Kelsi M Sandoz; Steven G Eriksen; Brendan M Jeffrey; Robert J Suchland; Timothy E Putman; Dennis E Hruby; Robert Jordan; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

3.  Frequency of spontaneous mutations that confer antibiotic resistance in Chlamydia spp.

Authors:  Rachel Binet; Anthony T Maurelli
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  In vivo and in vitro studies of Chlamydia trachomatis TrpR:DNA interactions.

Authors:  John H Carlson; Heidi Wood; Christine Roshick; Harlan D Caldwell; Grant McClarty
Journal:  Mol Microbiol       Date:  2006-03       Impact factor: 3.501

5.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

Review 6.  An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.

Authors:  Ahmed Moussa; Fouzia Radouani; Ichrak Benamri; Maryame Azzouzi; Kholoud Sanak
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-09-03       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.